With the 10-year Treasury sitting at 4.7% and the 30-year yield breaching 5.2%, growth stocks are facing a textbook double squeeze. Future earnings multiples are being compressed right when fiscal debt issuance is competing directly with corporate data center bonds for market liquidity. Here is how to think about positioning ahead of Kevin Warsh’s keynote address: Equities (Tech/QQQ): High sensitivity to long-end yields. With Nvidia's solid Q2 performance already digesting, any hawkish tone on balance sheet runoff or persistent inflation (Core PCE running at 3.3%) could trigger short-term multiple compression across high-beta tech. Keeping risk management strict on leveraged positions is key. Gold: Acting as the clear winner in this macro environment (+0.75%). It continues to serve as an e

Ripple Effect on AI Memory & Packaging: NVIDIA’s massive capital expenditure is redirecting market focus toward key supply-chain partners—particularly High Bandwidth Memory (HBM) suppliers and advanced packaging foundries (such as SK Hynix, Micron, and TSMC). Macro Environment & Central Banks: Cooling energy prices and stabilizing inflation figures have eased interest rate anxieties. Meanwhile, regional central banks continue adjusting monetary policy (e.g., Bank of Korea raising rates).

Nvidia’s record revenue of $96.221 billion (+106% YoY) showcases unmatched AI demand, but rising memory costs squeezing Q4 gross margins to 71–72% present a clear short-term hurdle. While the Rubin production ramp and +4% after-hours gain boost confidence across supply chain peers, Nvidia’s history of next-day post-earnings dips means execution and margin defense will be critical to sustain this momentum.

$DBS(D05.SI)$  

The self-driving story isn't just back—it's finally being monetized. Wall Street has been discounting Tesla's FSD and autonomy potential for years, treating it purely as a car company. The Miami Robotaxi launch is the exact catalyst needed to permanently shift TSLA into a high-margin AI and robotics valuation. Paired with stable Q2 delivery data, the downside risk looks increasingly capped. $400 is just the floor now.

$DBS(D05.SI)$  

The 3.3% QQQ rebound catalyzed by strong Microsoft earnings and cooling June core PCE at 3.3% demonstrates that resilient fundamental AI revenue and solid tech balance sheets can snap losing streaks and provide a strong market floor. However, with market skepticism toward Fed policy remaining high until concrete rate cuts materialize, and August historically bringing seasonal light volume volatility, this rally is unlikely to be a smooth upward march. Investors should view this as an earnings driven relief bounce rather than a full structural regime shift, using short term strength to stay selective and keep dry powder ready for potential late summer pullbacks.

The divergence between Wall Street’s "buy" ratings and BofA’s cautious target perfectly highlights the valuation struggle with a company like SpaceX. On one hand, Starlink dominates global satellite internet, and Starship represents a complete monopoly on heavy-lift launch capability.On the other hand, a $152 price point prices in absolute perfection for years to come. The decision by some new ETFs to explicitly exclude Musk-linked assets adds an extra layer of non-fundamental risk (key-man risk and political volatility). I wouldn't call it a "falling knife" just yet given the underlying fundamentals, but chasing this specific rebound without seeing a consolidated base form is highly risky.

It depends on your risk tolerance: conservative investors should rotate to Merck, while high-conviction traders should wait for the full Phase 3 dataset. Moderna’s 14% pop reflects a short-covering squeeze and repricing of pipeline optionality following Wolfe Research’s upgrade to Peer Perform. However, holding at $158+ requires high conviction: the $9.2B peak sales figure is an unadjusted wall-street model assumption across multiple indications—not active product orders—and must be split 50/50 with partner Merck. Furthermore, Moderna's trailing twelve-month revenue has declined 27.6% to $2.23B, and detailed numerical Phase 3 INTerpath-001 data (including overall survival and hazard ratios) has not yet been peer-reviewed or fully presented.

The underlying AI structural narrative isn't broken—SK Hynix still secured major long-term customer agreements and record quarterly profits. However, the stock is resetting from overextended sentiment back toward grounded valuation metrics.